Table 1.
Initial Clinical Characteristics
| |
Stimulated thyroglobulin (ng/mL) |
|
||
|---|---|---|---|---|
| 2.0–4.9 (n=80) | 5.0–19.9 (n=66) | ≥20 (n=40) | p | |
| Age (years) | 41±11 | 42±13 | 42±13 | 0.830 |
| Sex, male | 14 (18%) | 9 (14%) | 11 (28%) | 0.196 |
| Tumor size (cm) | 2.1±1.3 | 2.3±1.1 | 3.1±1.7 | 0.002 |
| Pathology | 0.749 | |||
| PTC | 79 (99%) | 65 (99%) | 40 (100%) | |
| FTC | 1 (1%) | 1 (1%) | 0 | |
| Initial operation extent | 0.002 | |||
| Total thyroidectomy | 10 (13%) | 3 (5%) | 2 (5%) | |
| Plus CND | 56 (70%) | 50 (76%) | 19 (48%) | |
| Plus MRND | 14 (18%) | 13 (20%) | 19 (48%) | |
| Remove LN | 10 (0–75) | 9 (0–63) | 11 (0–105) | 0.051 |
| Malignant LN | 4 (0–25) | 4 (0–26) | 7 (0–44) | 0.004 |
| T stage | 0.013 | |||
| T1 | 21 (26%) | 8 (12%) | 5 (13%) | |
| T2 | 3 (4%) | 9 (14%) | 4 (10%) | |
| T3 | 55 (69%) | 46 (70%) | 26 (65%) | |
| T4 | 1 (1%) | 3 (5%) | 3 (13%) | |
| N stage | 0.002 | |||
| N0 | 22 (28%) | 7 (11%) | 2 (5%) | |
| N1a | 43 (54%) | 43 (65%) | 21 (53%) | |
| N1b | 15 (19%) | 16 (24%) | 17 (43%) | |
| AJCC TNM stage | 0.278 | |||
| I/II | 54 (68%) | 41 (62%) | 21 (53%) | |
| III/IV | 26 (33%) | 25 (38%) | 19 (48%) | |
| Ablation RAI dose | 0.131 | |||
| 30 mCi | 6 (8%) | 1 (2%) | 1 (3%) | |
| 75 mCi | 10 (13%) | 6 (9%) | 1 (3%) | |
| 150 mCi | 64 (80%) | 59 (89%) | 38 (95%) | |
The numbers in parentheses are percentages or ranges.
PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; CND, central neck dissection; MRND, modified radical neck dissection; LN, lymph node; RAI, radioactive iodine.